Figure 1.

Assessed for eligibility (n=74)
- Excluded (n=8)
  - Not meeting inclusion criteria (n=0)
  - Declined to participate (n=8)

Randomized (n = 66)

Allocation
- Allocated to placebo (n=21)
  - Received allocated intervention (n=21)
- Allocated to TGD 300 mg/d (n=23)
  - Received allocated intervention (n=23)
- Allocated to TGD 900 mg/d (n=22)
  - Received allocated intervention (n=22)

Follow-Up
- Lost to follow-up (n=1)
  - Stopped medication (n=1)
- Lost to follow-up (n=3)
  - Stopped medication (n=2)
  - Hospitalization (n=1)
- Lost to follow-up (n=2)
  - Stopped medication (n=2)

Analysis
- Analyzed before treatment (n=20)
  - Excluded from analysis (n=0)
  - Analyzed after treatment (n=16)
  - Lost the fecal sampling after treatment (n=4)
- Analyzed before treatment (n=20)
  - Excluded from analysis (n=0)
  - Analyzed after treatment (n=16)
  - Lost the fecal sampling after treatment (n=4)
- Analyzed before treatment (n=20)
  - Excluded from analysis (n=0)
  - Analyzed after treatment (n=17)
  - Lost the fecal sampling after treatment (n=3)